Devicor Buys Rights to Tissue Marker

David Rosenfeld | | Radiology Business | Business Intelligence
Devicor Medical Products Inc. has signed exclusive rights to market a new beta-glucan tissue marker used in breast biopsies. The company bought the rights from Carbon Medical Technologies. Devicor is owned by Mammotome, a worldwide leader of biopsy site markers and vacuum-assisted biopsy devices, according to a company press release. "Doctors have told us that consistent and long-lasting visibility under ultrasound and other imaging modalities is important for the treatment of their patients. We believe this product provides that solution," stated Tom Daulton, CEO of Devicor and Mammotome, in the release.

David Rosenfeld

Related Content

Mexico, not China, is biggest tariff concern among radiology vendors
DirectMed Imaging acquires Richardson Healthcare
Medical imaging trends to watch in 2025
Concerns about private equity's growing influence in radiology
Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%

Around the web

Health Imaging
American College of Radiology announces significant expansion of Lung Cancer Screening Registry

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

Health Imaging
AI reduces CT lung cancer screening workload by nearly 80%

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.